治療用ワクチン市場：ワクチンタイプ別、適応疾患別、投与法別、エンドユーザー別-2023-2030年の世界予測

治療用ワクチンの世界市場は、2023年に300億8,000万米ドル、CAGR 10.28%で大幅な成長が予測され、2030年には599億5,000万米ドルという驚異的な規模に達する見込みです。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは世界の治療用ワクチン市場を評価するために不可欠です。事業戦略と製品満足度の主要指標を調査することで、ベンダーの包括的な評価を提供し、ユーザーは特定のニーズに基づいた情報をもとに意思決定を行うことができます。この高度な分析により、ベンダーは成功の度合いが異なる4つの象限に整理されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析では、特定の市場領域におけるベンダーの現状を洞察することができます。全体的な収益、顧客基盤、その他の主要指標に対するベンダーの貢献度を比較することで、企業が市場シェアを争う際に、自社の業績や直面している状況をより深く理解することができます。また、本分析では、調査した基準年において、特定のセクターがどの程度競合しているのか、蓄積、断片化の優位性、合併の特徴についても明らかにしています。

本レポートは、以下のポイントに関する洞察を提供します：

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提供します。

2.市場の発展：有利な新興市場に関する詳細情報を提供し、市場の成熟セグメントにおける浸透度を分析します。

3.市場の多様化：新製品の上市、未開発地域、最近の開発、投資に関する詳細情報を提供します。

4.市場の動向：COVID-19、ロシア・ウクライナ紛争、高インフレの累積的な影響を包括的に理解することができます。

5.競合の評価と情報：主要企業の市場シェア、戦略、製品、認証、規制状況、特許状況、製造能力を網羅的に評価します。

6.製品開発およびイノベーション：将来技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような質問にお答えします：

1.治療用ワクチンの世界市場規模および予測は？

2.予測期間中、世界の治療用ワクチン市場を形成するCOVID-19の阻害要因と影響は？

3.治療用ワクチンの世界市場において予測期間中に投資すべき製品/セグメント/アプリケーション/分野は？

4.治療用ワクチンの世界市場における競争戦略は？

5.治療用ワクチンの世界市場における技術動向と規制の枠組みは？

6.治療用ワクチンの世界市場における主要ベンダーの市場シェアは？

7.治療用ワクチンの世界市場への参入には、どのような形態や戦略的な動きが適していると考えられるか？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 慢性疾患や感染症などの病気の有病率の上昇
    • 生物学的製剤および対象疾患に対する医薬品の需要の高まり
    • ワクチン開発に対する政府の資金提供の拡大
  • 抑制要因
    • 治療用ワクチンに関連する副作用
    • ワクチン承認に対する政府の厳しい規制
  • 機会
    • ワクチン接種を進めるための政府および民間団体の取り組みの拡大
    • ペプチドベースの治療用ワクチンや肺炎球菌ワクチンなどの新規ワクチンのイントロダクション
    • 研究開発活動の増加とワクチン開発のパイプライン
  • 課題
    • 一部のワクチン製造の臨床試験の処理が遅い
    • 治療用ワクチンの開発に伴う高額なコスト
• 市場動向
• COVID-19の累積的な影響
• ロシア・ウクライナ紛争の累積的影響
• 高インフレの累積的影響
• ポーターのファイブフォース分析
• バリューチェーンとクリティカルパス分析
• 規制の枠組み
• 顧客のカスタマイズ

第6章 治療用ワクチン市場ワクチンの種類別

• 自己免疫疾患ワクチン
• 慢性疾患ワクチン
• 感染症ワクチン
• 神経疾患ワクチン

第7章 治療用ワクチン市場：疾患適応症別

• デング熱
• DTP
• 肝炎
• ヒトパピローマウイルス
• インフルエンザ
• 髄膜炎菌性疾患
• MMR
• 肺炎球菌疾患
• ポリオ
• 水痘

第8章 治療用ワクチン市場行政別

• 筋肉内および皮下投与
• 経口投与

第9章 治療用ワクチン市場：エンドユーザー別

• 大人
• 小児科

第10章 南北アメリカの治療用ワクチン市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域の治療用ワクチン市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカの治療用ワクチン市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• FPNVポジショニングマトリクス
• 市場シェア分析：主要企業別
• 競合シナリオ分析：主要企業別

第14章 掲載企業一覧

第15章 付録

• ディスカッションガイド
• ライセンスと価格について

LIST OF FIGURES

• FIGURE 1. THERAPEUTIC VACCINES MARKET RESEARCH PROCESS
• FIGURE 2. THERAPEUTIC VACCINES MARKET SIZE, 2022 VS 2030
• FIGURE 3. THERAPEUTIC VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2022 VS 2030 (%)
• FIGURE 5. THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2022 VS 2030 (%)
• FIGURE 6. THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2022 VS 2030 (%)
• FIGURE 7. THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2022 VS 2030 (%)
• FIGURE 8. THERAPEUTIC VACCINES MARKET SIZE, BY REGION, 2022 VS 2030 (%)
• FIGURE 9. THERAPEUTIC VACCINES MARKET DYNAMICS
• FIGURE 10. THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 11. THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 12. THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 13. THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 15. UNITED STATES THERAPEUTIC VACCINES MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 17. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 18. THERAPEUTIC VACCINES MARKET, FPNV POSITIONING MATRIX, 2022
• FIGURE 19. THERAPEUTIC VACCINES MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

• TABLE 1. THERAPEUTIC VACCINES MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
• TABLE 3. THERAPEUTIC VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
• TABLE 5. THERAPEUTIC VACCINES MARKET SIZE, BY AUTO-IMMUNE DISEASES VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 6. THERAPEUTIC VACCINES MARKET SIZE, BY CHRONIC DISEASE VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 7. THERAPEUTIC VACCINES MARKET SIZE, BY INFECTIOUS DISEASES VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 8. THERAPEUTIC VACCINES MARKET SIZE, BY NEUROLOGICAL DISEASE VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 10. THERAPEUTIC VACCINES MARKET SIZE, BY DENGUE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. THERAPEUTIC VACCINES MARKET SIZE, BY DTP, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. THERAPEUTIC VACCINES MARKET SIZE, BY HEPATITIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. THERAPEUTIC VACCINES MARKET SIZE, BY HUMAN PAPILLOMA VIRUS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. THERAPEUTIC VACCINES MARKET SIZE, BY INFLUENZA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. THERAPEUTIC VACCINES MARKET SIZE, BY MENINGOCOCCAL DISEASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. THERAPEUTIC VACCINES MARKET SIZE, BY MMR, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. THERAPEUTIC VACCINES MARKET SIZE, BY PNEUMOCOCCAL DISEASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. THERAPEUTIC VACCINES MARKET SIZE, BY POLIO, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. THERAPEUTIC VACCINES MARKET SIZE, BY VARICELLA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 21. THERAPEUTIC VACCINES MARKET SIZE, BY INTRAMUSCULAR & SUBCUTANEOUS ADMINISTRATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. THERAPEUTIC VACCINES MARKET SIZE, BY ORAL ADMINISTRATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 24. THERAPEUTIC VACCINES MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. THERAPEUTIC VACCINES MARKET SIZE, BY PEDIATRICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. AMERICAS THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 27. AMERICAS THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
• TABLE 28. AMERICAS THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 29. AMERICAS THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 30. AMERICAS THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 31. ARGENTINA THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
• TABLE 32. ARGENTINA THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 33. ARGENTINA THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 34. ARGENTINA THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 35. BRAZIL THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
• TABLE 36. BRAZIL THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 37. BRAZIL THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 38. BRAZIL THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 39. CANADA THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
• TABLE 40. CANADA THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 41. CANADA THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 42. CANADA THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 43. MEXICO THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
• TABLE 44. MEXICO THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 45. MEXICO THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 46. MEXICO THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 47. UNITED STATES THERAPEUTIC VACCINES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 48. UNITED STATES THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
• TABLE 49. UNITED STATES THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 50. UNITED STATES THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 51. UNITED STATES THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 52. ASIA-PACIFIC THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 53. ASIA-PACIFIC THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
• TABLE 54. ASIA-PACIFIC THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 55. ASIA-PACIFIC THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 56. ASIA-PACIFIC THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 57. AUSTRALIA THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
• TABLE 58. AUSTRALIA THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 59. AUSTRALIA THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 60. AUSTRALIA THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 61. CHINA THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
• TABLE 62. CHINA THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 63. CHINA THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 64. CHINA THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 65. INDIA THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
• TABLE 66. INDIA THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 67. INDIA THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 68. INDIA THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 69. INDONESIA THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
• TABLE 70. INDONESIA THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 71. INDONESIA THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 72. INDONESIA THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 73. JAPAN THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
• TABLE 74. JAPAN THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 75. JAPAN THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 76. JAPAN THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 77. MALAYSIA THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
• TABLE 78. MALAYSIA THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 79. MALAYSIA THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 80. MALAYSIA THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 81. PHILIPPINES THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
• TABLE 82. PHILIPPINES THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 83. PHILIPPINES THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 84. PHILIPPINES THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 85. SINGAPORE THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
• TABLE 86. SINGAPORE THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 87. SINGAPORE THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 88. SINGAPORE THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 89. SOUTH KOREA THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
• TABLE 90. SOUTH KOREA THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 91. SOUTH KOREA THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 92. SOUTH KOREA THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 93. TAIWAN THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
• TABLE 94. TAIWAN THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 95. TAIWAN THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 96. TAIWAN THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 97. THAILAND THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
• TABLE 98. THAILAND THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 99. THAILAND THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 100. THAILAND THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 101. VIETNAM THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
• TABLE 102. VIETNAM THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 103. VIETNAM THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 104. VIETNAM THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 105. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 106. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
• TABLE 107. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 108. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 109. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 110. DENMARK THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
• TABLE 111. DENMARK THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 112. DENMARK THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 113. DENMARK THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 114. EGYPT THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
• TABLE 115. EGYPT THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 116. EGYPT THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 117. EGYPT THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 118. FINLAND THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
• TABLE 119. FINLAND THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 120. FINLAND THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 121. FINLAND THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 122. FRANCE THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
• TABLE 123. FRANCE THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 124. FRANCE THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 125. FRANCE THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 126. GERMANY THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
• TABLE 127. GERMANY THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 128. GERMANY THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 129. GERMANY THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 130. ISRAEL THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
• TABLE 131. ISRAEL THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 132. ISRAEL THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 133. ISRAEL THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 134. ITALY THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
• TABLE 135. ITALY THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 136. ITALY THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 137. ITALY THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 138. NETHERLANDS THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
• TABLE 139. NETHERLANDS THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 140. NETHERLANDS THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 141. NETHERLANDS THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 142. NIGERIA THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
• TABLE 143. NIGERIA THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 144. NIGERIA THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 145. NIGERIA THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 146. NORWAY THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
• TABLE 147. NORWAY THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 148. NORWAY THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 149. NORWAY THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 150. POLAND THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
• TABLE 151. POLAND THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 152. POLAND THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 153. POLAND THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 154. QATAR THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
• TABLE 155. QATAR THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 156. QATAR THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 157. QATAR THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 158. RUSSIA THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
• TABLE 159. RUSSIA THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 160. RUSSIA THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 161. RUSSIA THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 162. SAUDI ARABIA THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
• TABLE 163. SAUDI ARABIA THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 164. SAUDI ARABIA THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 165. SAUDI ARABIA THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 166. SOUTH AFRICA THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
• TABLE 167. SOUTH AFRICA THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 168. SOUTH AFRICA THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 169. SOUTH AFRICA THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 170. SPAIN THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
• TABLE 171. SPAIN THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 172. SPAIN THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 173. SPAIN THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 174. SWEDEN THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
• TABLE 175. SWEDEN THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 176. SWEDEN THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 177. SWEDEN THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 178. SWITZERLAND THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
• TABLE 179. SWITZERLAND THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 180. SWITZERLAND THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 181. SWITZERLAND THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 182. TURKEY THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
• TABLE 183. TURKEY THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 184. TURKEY THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 185. TURKEY THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 186. UNITED ARAB EMIRATES THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
• TABLE 187. UNITED ARAB EMIRATES THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 188. UNITED ARAB EMIRATES THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 189. UNITED ARAB EMIRATES THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 190. UNITED KINGDOM THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
• TABLE 191. UNITED KINGDOM THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 192. UNITED KINGDOM THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 193. UNITED KINGDOM THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 194. THERAPEUTIC VACCINES MARKET, FPNV POSITIONING MATRIX, 2022
• TABLE 195. THERAPEUTIC VACCINES MARKET SHARE, BY KEY PLAYER, 2022
• TABLE 196. THERAPEUTIC VACCINES MARKET LICENSE & PRICING

The Global Therapeutic Vaccines Market is forecasted to grow significantly, with a projected USD 30.08 billion in 2023 at a CAGR of 10.28% and expected to reach a staggering USD 59.95 billion by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Therapeutic Vaccines Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Therapeutic Vaccines Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Vaccines Type, market is studied across Auto-Immune Diseases Vaccines, Chronic Disease Vaccines, Infectious Diseases Vaccines, and Neurological Disease Vaccines. The Chronic Disease Vaccines is projected to witness significant market share during forecast period.

Based on Disease Indication, market is studied across Dengue, DTP, Hepatitis, Human Papilloma Virus, Influenza, Meningococcal Disease, MMR, Pneumococcal Disease, Polio, and Varicella. The Meningococcal Disease is projected to witness significant market share during forecast period.

Based on Administration, market is studied across Intramuscular & Subcutaneous Administration and Oral Administration. The Oral Administration is projected to witness significant market share during forecast period.

Based on End-User, market is studied across Adults and Pediatrics. The Pediatrics is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.75% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Therapeutic Vaccines Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Therapeutic Vaccines Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Therapeutic Vaccines Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Therapeutic Vaccines Market?

4. What is the competitive strategic window for opportunities in the Global Therapeutic Vaccines Market?

5. What are the technology trends and regulatory frameworks in the Global Therapeutic Vaccines Market?

6. What is the market share of the leading vendors in the Global Therapeutic Vaccines Market?

7. What modes and strategic moves are considered suitable for entering the Global Therapeutic Vaccines Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Limitations
• 1.7. Assumptions
• 1.8. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

• 4.1. Introduction
• 4.2. Therapeutic Vaccines Market, by Vaccines Type, 2022 vs 2030
• 4.3. Therapeutic Vaccines Market, by Disease Indication, 2022 vs 2030
• 4.4. Therapeutic Vaccines Market, by Administration, 2022 vs 2030
• 4.5. Therapeutic Vaccines Market, by End-User, 2022 vs 2030
• 4.6. Therapeutic Vaccines Market, by Region, 2022 vs 2030

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising prevalence rate of diseases such as chronic and infectious diseases
    • 5.1.1.2. Rising demand for biologics and drugs for targeted diseases
    • 5.1.1.3. Growing government funding for vaccine development
  • 5.1.2. Restraints
    • 5.1.2.1. Side effects associated with therapeutic vaccines
    • 5.1.2.2. Stringent government regulations for the approval of vaccines
  • 5.1.3. Opportunities
    • 5.1.3.1. Growing initiatives from government and private organizations to advance vaccination
    • 5.1.3.2. Introduction of novel vaccines such as peptide-based therapeutic vaccines, and pneumococcal vaccines
    • 5.1.3.3. Rising R&D activities and vaccines developments in the pipeline
  • 5.1.4. Challenges
    • 5.1.4.1. Slow processing of clinical trials for the production of some vaccine
    • 5.1.4.2. High cost associated with the development of the therapeutic vaccines
• 5.2. Market Trends
• 5.3. Cumulative Impact of COVID-19
• 5.4. Cumulative Impact of Russia-Ukraine Conflict
• 5.5. Cumulative Impact of High Inflation
• 5.6. Porter's Five Forces Analysis
  • 5.6.1. Threat of New Entrants
  • 5.6.2. Threat of Substitutes
  • 5.6.3. Bargaining Power of Customers
  • 5.6.4. Bargaining Power of Suppliers
  • 5.6.5. Industry Rivalry
• 5.7. Value Chain & Critical Path Analysis
• 5.8. Regulatory Framework
• 5.9. Client Customization

6. Therapeutic Vaccines Market, by Vaccines Type

• 6.1. Introduction
• 6.2. Auto-Immune Diseases Vaccines
• 6.3. Chronic Disease Vaccines
• 6.4. Infectious Diseases Vaccines
• 6.5. Neurological Disease Vaccines

7. Therapeutic Vaccines Market, by Disease Indication

• 7.1. Introduction
• 7.2. Dengue
• 7.3. DTP
• 7.4. Hepatitis
• 7.5. Human Papilloma Virus
• 7.6. Influenza
• 7.7. Meningococcal Disease
• 7.8. MMR
• 7.9. Pneumococcal Disease
• 7.10. Polio
• 7.11. Varicella

8. Therapeutic Vaccines Market, by Administration

• 8.1. Introduction
• 8.2. Intramuscular & Subcutaneous Administration
• 8.3. Oral Administration

9. Therapeutic Vaccines Market, by End-User

• 9.1. Introduction
• 9.2. Adults
• 9.3. Pediatrics

10. Americas Therapeutic Vaccines Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Therapeutic Vaccines Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Therapeutic Vaccines Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. FPNV Positioning Matrix
• 13.2. Market Share Analysis, By Key Player
• 13.3. Competitive Scenario Analysis, By Key Player

14. List of Company Mentioned

15. Appendix

• 15.1. Discussion Guide
• 15.2. License & Pricing